Newsroom | 87290 results

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 33,650 shares of Astria’s common stock on May 1, 2025 under Astria’s 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astria. The options were granted...

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on May 1, 2025, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 164,500 shares of common stock to nine new employees under the Company’s 2024 Induceme...

LAUSANNE, Switzerland & SAN DIEGO--(BUSINESS WIRE)--HAYA Therapeutics to Present on RNA-guided Regulatory Genome Platform at the Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)...

LOS ANGELES--(BUSINESS WIRE)--The official trailer for “Shelter Me: The Cancer Pioneers” has just dropped, giving audiences a moving first look at the groundbreaking new documentary that follows the emotional and inspiring journey of dogs helping to pioneer cancer treatments that are saving human lives. The movie will stream through the PBS app and on PBS.org starting on Thursday, May 15. The newest film in the Emmy Award-winning “Shelter Me” series, ‘The Cancer Pioneers’ brings viewers inside...

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, announced that Aditxt’s CIO Dr. Shahrokh Shabahang, and Adimune’s Co-CEO Dr. Friedrich Kapp, will join today’s Aditxt Weekly Update to discuss recent developments related to ADI-100™, the lead therapeutic candidate of its wholly owned subsidiary, Adimune. Event Details: Title: Aditxt Weekly Update Date: Friday, May 2, 2025 Time:...

RALEIGH, N.C.--(BUSINESS WIRE)--Gemelli Biotech's Trio-Smart® 3-Gas Breath Test Featured at DDW 2025....

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its first quarter ended March 31, 2025. First Quarter 2025 Results: Total Revenue of $73.5 million Core Revenue1 grew 16% year-over-year to $73.5 million GAAP loss of $11.5 million, or ($0.37) per share Non-GAAP income of $1.2 million, o...

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the compensation committee of KalVista’s board of directors granted three newly-hired employees inducement options to purchase an aggregate of 14,000 shares of KalVista common stock on May 1, 2025 as inducements material to each employee entering into employment with KalVista. The options have an exercise price that is equal to the closing price of KalVista common stock on...

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced that the Compensation Committee of the company’s Board of Directors, made up entirely of independent directors, approved the grant of non-qualified stock options to purchase an aggregate of 204,150 shares of the company’s common stock to 13 new employees (t...

WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that AstraZeneca’s fixed-dose triple-combination therapy BREZTRI AEROSPHERE (budesonide/glycopyrronium/formoterol fumarate or BGF (320/28.8/9.6μg)) met all primary endpoints, demonstrating a statistically significant and clinically meaningful improvement in lung function compared with dual-combination inhaled corticosteroid/long-acting beta2-agonis...